Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00389584 · ClinicalTrials.gov registry record · Phase 1
Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors
A Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Brain and Central Nervous System Tumors, sponsored by University of California, Davis.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00389584: Completed Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Brain and Central Nervous System Tumors, sponsored by University of California, Davis.
NCT00389584 is a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Brain and Central Nervous System Tumors that has completed, run by University of California, Davis. The registered enrollment target is 30 participants, below the 501-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00389584, a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Brain and Central Nervous System Tumors, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Irinotecan may make tumor cells more sensitive to radiation therapy. Giving irinotecan together with whole-brain radiation therapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of irinotecan when given together with whole-brain radiation therapy and to see how well they work in treating patients with brain metastases from solid tumors. (The study of side effects and best dose has ended as of 4/15/05)
Conditions Studied
Interventions
- RADIATION radiation therapy
- PROCEDURE cognitive assessment
- DRUG irinotecan hydrochloride
- PROCEDURE management of therapy complications
Study Locations (1)
California
- University of California Davis Cancer Center - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2002-12 |
| Est. Completion | 2006-11 |
| Phase | Phase 1 |
What the finished NCT00389584 record still lists
NCT00389584 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 501-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (94% lower).
The record links to 7 conditions, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 4 interventions - of which radiation therapy is the first listed.
NCT00389584 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00389584 about?
NCT00389584 is a clinical study titled "Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors". RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Irinotecan may make tumor cells more sensitive to radiati...
What is the current status of trial NCT00389584?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2002-12. Estimated completion is 2006-11.
What conditions does trial NCT00389584 study?
This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific, Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific, Cognitive/Functional Effects, Long-term Effects Secondary to Cancer Therapy in Adults.
What interventions are being tested in trial NCT00389584?
The interventions under investigation include: radiation therapy (RADIATION), cognitive assessment (PROCEDURE), irinotecan hydrochloride (DRUG), management of therapy complications (PROCEDURE).
Who is sponsoring clinical trial NCT00389584?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00389584 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unspecified Adult Solid Tumor, Protocol Specific
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00389584's enrollment target sits among peer trials
30 52nd of 83 higher than 30 of 83 other Unspecified Adult Solid Tumor, Protocol Specific trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Unspecified Adult Solid Tumor, Protocol Specific trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists
ACTIVE NOT RECRUITING · Phase 1
-
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
COMPLETED · Phase 1
-
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
BMS-599626 in Treating Patients With Metastatic Solid Tumors
COMPLETED · Phase 1
-
Indole-3-Carbinol in Preventing Cancer in Healthy Participants
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia